Notes in Hodgkin lymphoma

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	Paeds \| Haem \| HL \| 1.1 \| Epidemiology
Published	02/18/2024	Paeds \| Haem \| HL \| 1.2 \| Aetiology
Published	02/18/2024	Paeds \| Haem \| HL \| 1.3 \| Pathology
Published	02/18/2024	Paeds \| Haem \| HL \| 2.1 \| Workup
Published	02/18/2024	Paeds \| Haem \| HL \| 2.2 \| Staging
Published	02/18/2024	Paeds \| Haem \| HL \| 1.5 \| Biologic behaviour
Published	02/18/2024	Paeds \| Haem \| HL \| 2.3 \| Risk stratification
Published	02/18/2024	Paeds \| Haem \| HL \| 2.4 \| Outcomes
Published	02/18/2024	Paeds \| Haem \| HL \| 3.1 \| Management overview
Published	02/18/2024	Paeds \| Haem \| HL \| 3.3 \| Late toxicity
Published	02/18/2024	Paeds \| Haem \| HL \| 3.4 \| Risk adapted therapy
Published	02/18/2024	Paeds \| Haem \| HL \| 1.4 \| Clinical presentation
Published	02/18/2024	Paeds \| Haem \| HL \| 3.2 \| Summary of key evidence
Published	02/18/2024	Paeds \| Haem \| HL \| 4 \| Treatment technique
Published	02/18/2024	Paeds \| Haem \| HL \| 3.5 Relapsed and refractory disease
Status	Last Update	Fields